ASCO 2026: Breakthrough Data in Myeloma and Lung Cancer Reshape Treatm

The Science

The American Society of Clinical Oncology (ASCO) annual meeting is the premier global oncology event, drawing thousands of researchers, clinicians, and industry leaders. This year, Bristol Myers Squibb and Pfizer stole the spotlight with promising data in multiple myeloma and non-small cell lung cancer (NSCLC), respectively. These results could reshape treatment paradigms for thousands of patients who have exhausted standard options. The data, presented in late-breaking abstract sessions, represent the culmination of years of preclinical and clinical development.

“The single most important takeaway: both therapies demonstrated meaningful improvements in progression-free survival in heavily pretreated populations, with manageable safety profiles that support chronic dosing.”

Key Findings

• Bristol Myers in multiple myeloma: Phase 3 trial data showed a 40% reduction in the risk of disease progression or death compared to standard of care in patients who had received at least three prior lines of therapy, including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies. The median progression-free survival was 18.3 months in the experimental arm versus 11.2 months in the control arm, with an overall response rate of 65%. The combination includes a BCMA-targeting bispecific antibody and a next-generation immunomodulatory agent, designed to overcome resistance mechanisms.
• Pfizer in lung cancer: The KRAS G12C inhibitor achieved a 40% objective response rate in patients with advanced NSCLC harboring the KRAS G12C mutation, with median progression-free survival exceeding 8 months and median duration of response of 10.5 months. This is particularly significant because approximately 13% of NSCLC patients carry this mutation, and prior options were limited to chemotherapy or immunotherapy with modest efficacy. The drug covalently binds to the mutant KRAS protein, locking it in an inactive state.
• Safety profile: Grade 3 or higher adverse events occurred in less than 15% of patients across both trials, indicating manageable toxicity. Common side effects included fatigue, nausea, and diarrhea, but rarely led to treatment discontinuation. No new safety signals emerged that would halt development. Importantly, the safety profiles support long-term administration, which is critical for maintaining disease control.

Why It Matters

These advances validate targeted approaches in difficult-to-treat cancers. In multiple myeloma, Bristol's combination therapy addresses resistance mechanisms that limit current options. The bispecific antibody engages T cells to kill myeloma cells expressing BCMA, while the immunomodulatory agent enhances immune activation and directly inhibits tumor growth. This dual mechanism has shown efficacy even in patients refractory to prior therapies.

In NSCLC, Pfizer's drug offers a much-needed option for the 13% of patients with KRAS G12C mutations. For years, KRAS was considered "undruggable," but the development of specific inhibitors has opened a new era in targeted therapy. The success of this drug validates the approach of targeting specific conformational states of mutant proteins. Moreover, it paves the way for combination studies with other agents, such as MEK inhibitors or immune checkpoint blockers, to enhance and prolong responses.

For patients, these data translate into tangible hope. Improved response rates and manageable side effects mean more effective and tolerable treatment. Oncologists gain new tools to customize therapy based on genetic profiles. The importance of routine genetic testing cannot be overstated; identifying actionable mutations like KRAS G12C or targets like BCMA is now essential for optimal treatment planning.

Your Protocol

If you or a loved one are affected by these cancers:

1. 1Discuss genetic testing with your oncologist to determine if you are a candidate for these targeted therapies. For lung cancer, request testing for KRAS G12C and other actionable mutations (EGFR, ALK, ROS1, BRAF). For multiple myeloma, ask about BCMA expression testing or eligibility for bispecific antibody therapies.
2. 2Inquire about clinical trial availability; these treatments may be accessible through expanded access programs or ongoing trials. Search clinicaltrials.gov for studies involving these agents, and consider contacting major cancer centers that participate in early-phase trials. Many trials offer travel reimbursement and free study medication.
3. 3Stay updated on FDA approvals expected within the next 6-12 months. Both drugs have received breakthrough therapy designation, which expedites review. Monitor FDA announcements and NCCN guideline updates, which may incorporate these therapies as preferred regimens.
4. 4Adopt a comprehensive approach: in addition to medical treatment, maintain a balanced diet, engage in moderate physical activity, and seek psychological support. Evidence shows that patients who actively participate in their care have better outcomes. Consider integrative oncology services such as nutrition counseling, exercise programs, and stress management.

Prevention remains paramount: avoid smoking, maintain a healthy diet, and undergo recommended screenings. For lung cancer, low-dose CT screening is recommended for high-risk individuals (current or former smokers aged 50-80 with a 20 pack-year history). For multiple myeloma, no routine screening exists, but awareness of symptoms (bone pain, fatigue, recurrent infections) can lead to earlier diagnosis.

What To Watch Next

Full data presentations at ASCO will include overall survival analyses and subgroup outcomes by age, sex, and prior treatment. Regulatory submissions to the FDA are anticipated in the coming months, with decisions expected by late 2026. Additionally, combination studies with immunotherapies and other targeted agents are already underway.

In multiple myeloma, trials combining Bristol's bispecific antibody with CAR-T cell therapy are in development, potentially offering deeper and more durable responses. In NSCLC, combinations of the KRAS G12C inhibitor with PD-1/PD-L1 inhibitors are being tested to overcome acquired resistance and improve response rates.

The oncology community will watch for long-term survival data that could cement these therapies as new standards of care. Predictive biomarkers, such as tumor mutational burden or PD-L1 expression, may emerge to guide patient selection. Real-world evidence from expanded access programs will also provide insights into effectiveness in broader populations.

The Bottom Line

ASCO 2026 delivers strong signals of progress. Bristol Myers and Pfizer have provided robust evidence for their therapies. While clinical implementation takes time, the trajectory is clear: precision oncology is advancing, offering patients more effective and personalized options. The future of cancer treatment looks brighter than ever, with targeted therapies and immunotherapies converging to improve outcomes. Staying informed and actively engaging in treatment decisions is the best strategy to leverage these advances.